The enhanced energy metabolism in the tumor margin mediated by RRAD promotes the progression of oral squamous cell carcinoma

• Published in: Cell death & disease Vol. 15; no. 5; pp. 376 - 14
• Main Authors: Cheng, Aoming, Xu, Qiaoshi, Li, Bo, Zhang, Lirui, Wang, Hao, Liu, Chang, Han, Zhengxue, Feng, Zhien
• Format: Journal Article
• Language: English
• Published: England Springer Nature B.V 29.05.2024; Nature Publishing Group UK; Nature Publishing Group
• Subjects: Animals; Ca2+/calmodulin-dependent protein kinase IV; Calcium - metabolism; Carcinoma, Squamous Cell - genetics; Carcinoma, Squamous Cell - metabolism; Carcinoma, Squamous Cell - pathology; Cell Line, Tumor; Disease Progression; Down-regulation; Energy Metabolism; Gene Expression Regulation, Neoplastic; Glucose - metabolism; Glucose transporter; Glucose Transporter Type 3 - genetics; Glucose Transporter Type 3 - metabolism; Glycolysis; Humans; Metabolism; Metabolomics; Metastases; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms - genetics; Mouth Neoplasms - metabolism; Mouth Neoplasms - pathology; Oral cancer; Oral carcinoma; Oral squamous cell carcinoma; Squamous cell carcinoma; Transcriptomes; Tumor cells; Tumors
• ISSN: 2041-4889; 2041-4889
• DOI: 10.1038/s41419-024-06759-7

The tumor margin as the invasive front has been proven to be closely related to the progression and metastasis of oral squamous cell carcinoma (OSCC). However, how tumor cells in the marginal region obtain the extra energy needed for tumor progression is still unknown. Here, we used spatial metabolomics and the spatial transcriptome to identify enhanced energy metabolism in the tumor margin of OSCC and identified that the downregulation of Ras-related glycolysis inhibitor and calcium channel regulator (RRAD) in tumor cells mediated this process. The absence of RRAD enhanced the ingestion of glucose and malignant behaviors of tumor cells both in vivo and in vitro. Mechanically, the downregulation of RRAD promoted the internal flow of Ca and elevated its concentration in the nucleus, which resulted in the activation of the CAMKIV-CREB1 axis to induce the transcription of the glucose transporter GLUT3. GLUT inhibitor-1, as an inhibitor of GLUT3, could suppress this vigorous energy metabolism and malignant behaviors caused by the downregulation of RRAD. Taken together, our study revealed that enhanced energy metabolism in the tumor margin mediated by RRAD promotes the progression of OSCC and proved that GLUT3 is a potential target for future treatment of OSCC.